A High Response Rate to Liposomal Doxorubicin Is Seen Among Women With BRCA Mutations Treated for Recurrent Epithelial Ovarian Cancer

Gynecologic Oncology - United States
doi 10.1016/j.ygyno.2011.08.032
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Non‑pegylated Liposomal Doxorubicin for Patients With Recurrent Ovarian Cancer: A Multicentric Phase II Trial

Oncology Letters
Cancer ResearchOncology
2016English

BRCA Mutations in Women With Inflammatory Breast Cancer

Cancer
Cancer ResearchOncology
2017English

A Case of Metaplastic Breast Cancer With Prolonged Response to Single Agent Liposomal Doxorubicin

Cureus
2016English

Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin

Clinical Medicine Reviews in Women's Health
2010English

Preterm Delivery Is Associated With an Increased Risk of Epithelial Ovarian Cancer Among Parous Women

International Journal of Cancer
Cancer ResearchOncology
2018English

Phase 1 Trial of Olaparib and Oral Cyclophosphamide in BRCA Breast Cancer, Recurrent BRCA Ovarian Cancer, Non-Brca Triple-Negative Breast Cancer, and Non-Brca Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

A Systematic Review and Economic Evaluation of Pegylated Liposomal Doxorubicin Hydrochloride for Ovarian Cancer

Health Technology Assessment
MedicineHealth Policy
2002English

BRCA Mutations in the Manifestation and Treatment of Ovarian Cancer

Oncotarget
Oncology
2017English

Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer

JAMA - Journal of the American Medical Association
Medicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy